Gynecologic Oncology | Specialty

The OncLive Gynecologic Oncology condition center page is a comprehensive resource for clinical news and expert insights on various types of gynecologic cancers, including ovarian cancer, endometrial cancer, and uterine cancer, among others. This section features news articles, interviews with gynecologic oncologists in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in gynecologic cancers.

Dr. Backes on Quality of Life With PARP Inhibitors in Ovarian Cancer

February 7th 2020

Floor J. Backes, MD, discusses quality of life with PARP inhibitors for patients with ovarian cancer.

Niraparib Emerges as a Frontline Maintenance Standard in Advanced Ovarian Cancer

February 6th 2020

Antonio González-Martín, MD, discusses the design and findings of the PRIMA trial in advanced ovarian cancer.

Dr. Coleman on the Use of Veliparib in Ovarian Cancer

January 29th 2020

Robert L. Coleman, MD, FACOG, FACS, professor and Ann Rife Cox Chair in Gynecology, Department of Gynecologic Oncology and Reproductive Medicine, Division of Surgery, The University of Texas MD Anderson Cancer Center, discusses the use of veliparib in ovarian cancer.

Dr. Gonzalez-Martin on the Impact of the PRIMA Trial in Advanced Ovarian Cancer

January 29th 2020

Antonio Gonzalez-Martin, MD, co-director, Department of Medical Oncology, Clinica Universidad de Navarra, discusses the impact of the phase III PRIMA trial findings on clinical practice in advanced ovarian cancer.

Dr. Duska on the Utility of the Fagotti Score in Advanced Ovarian Cancer

January 29th 2020

Linda R. Duska, MD, professor of obstetrics and gynecology and gynecologic oncologist at the University of Virginia, explains whether the Fagotti score provides an accurate assessment of whether a patient with newly diagnosed, advanced ovarian cancer can achieve a complete resection in surgery.

Dr. Taylor on Molecular Testing Recommendations in Ovarian Cancer

January 29th 2020

Sarah E. Taylor, MD, discusses molecular testing recommendations in ovarian cancer.

Dr. Fowler on Selection Criteria for Surgical Procedures in Ovarian Cancer

January 29th 2020

Jeffrey M. Fowler, MD, discusses selection criteria that can help determine which surgical procedure to pursue in ovarian cancer.

Dr. Boisen on Neoadjuvant Chemotherapy Versus Upfront Surgery in Ovarian Cancer

January 29th 2020

Michelle M. Boisen, MD, discusses the selection of neoadjuvant chemotherapy versus upfront surgery for women with newly diagnosed ovarian cancer.

Frontline Veliparib Regimen Viable Approach in Advanced Ovarian Cancer

January 28th 2020

Robert L. Coleman, MD, FACOG, FACS, discusses the VELIA trial and the impact the results are going to have on the use of PARP inhibitors in ovarian cancer.

Dr. Orr on Ongoing Biomarker Research in Ovarian Cancer

January 28th 2020

Brian Orr, MD, an assistant professor in the Department of Obstetrics, Gynecology & Reproductive Sciences at University of Pittsburgh Medical Center, discusses ongoing biomarker research for immunotherapy in ovarian cancer.

Dr. Salani on Patient Selection for Primary Debulking Surgery in Ovarian Cancer

January 25th 2020

Ritu Salani, MD, discusses selecting patients with ovarian cancer for primary debulking surgery versus neoadjuvant chemotherapy.

Surgical Advances Improve QoL in Gynecologic Cancers

January 24th 2020

Mira Hellmann, MD, discusses surgical and systemic advancements in the field of gynecologic oncology.

Dr. Cosgrove on the Approval of Niraparib in Advanced Ovarian Cancer

January 24th 2020

Casey M. Cosgrove, MD, discusses the approval of niraparib in advanced ovarian cancer.

Dr. Backes on Toxicity Considerations With PARP Inhibitors in Ovarian Cancer

January 23rd 2020

Floor J. Backes, MD, discusses toxicity considerations with PARP inhibitors in ovarian cancer.

Dr. Coleman on Implications of the VELIA Trial in Ovarian Cancer

January 21st 2020

Robert L. Coleman, MD, FACOG, FACS, professor and Ann Rife Cox Chair in Gynecology, Department of Gynecologic Oncology and Reproductive Medicine, Division of Surgery, The University of Texas MD Anderson Cancer Center, discusses the implications of the phase III VELIA trial in ovarian cancer.

Dr. Moore on Benefit of Mirvetuximab Soravtansine in Ovarian Cancer

January 21st 2020

Kathleen Moore, MD, discusses the benefit of mirvetuximab soravtansine in patients with platinum-resistant ovarian cancer.

Dr. Copeland on the Role of Chemotherapy in Ovarian Cancer

January 18th 2020

Larry J. Copeland, MD, discusses the role of chemotherapy in ovarian cancer.

Dr. Hellmann on the Utility of Minimally Invasive Surgery in Cervical Cancer

January 18th 2020

Mira Hellmann, MD, discusses the utility of minimally invasive surgery in cervical cancer.

Dr. Schlumbrecht on Treatment in Uterine Leiomyosarcoma

January 17th 2020

Matthew P. Schlumbrecht, MD, discusses the treatment of women with uterine leiomyosarcoma.

NICE Recommends Olaparib Maintenance in Relapsed, Platinum-Sensitive Ovarian Cancer

January 16th 2020

The National Institute for Health and Care Excellence has recommended the use of olaparib as a maintenance treatment in adults with relapsed, platinum-sensitive, high-grade epithelial ovarian, fallopian tube, or primary peritoneal cancer.

NEXT PAGE
PREVIOUS PAGE